
6685921 : Authors Feedback Needed

9 pesan

Rajalakshmi Thanigaikumar <rajalakshmi.thanigaikumar@hindawi.com>

19 Desember 2020 15.51

Kepada: purwati@fk.unair.ac.id

Cc: budiono@fk.unair.ac.id, drbrianer@gmail.com, yulistiani@ff.unair.ac.id, andang-m@ff.unair.ac.id, nasronudin@fk.unair.ac.id, soroylardo@gmail.com, yongkieip@gmail.com, dr.fidhasutikno.lmg@gmail.com, ikerochmad@yahoo.co.id, stemcell.ind@gmail.com, shidayatriherwidhiyah@yahoo.com, dwisetyawan-90@ff.unair.ac.id, alfian-n-r-10@fk.unair.ac.id, herley-w-s@staf.unair.ac.id, wulan_wibowo77@yahoo.co.id, tpasmarawati@fk.unair.ac.id, erika.marfiani@fk.unair.ac.id, shinta.karina.yuniati-2014@fk.unair.ac.id, muhamad-r-u-f@fk.unair.ac.id, pepy.dr@fk.unair.ac.id, stemcell@itd.unair.ac.id, ehendrianto@staf.unair.ac.id, deyaka88@gmail.com, aristikadinar@gmail.com, nora.ertanti@gmail.com, igoihsan@gmail.com, discasandyakalapurnama@gmail.com, yuni.indrayani@gmail.com

Dear Purwati ,

This is regarding your manuscript " 6685921 " titled " A Randomized, Double-Blind, Multicenter Clinical Study for Comparing the Efficacy and Safety of Drug Combination of Lopinavir/Ritonavir-Azithromycin, Lopinavir/Ritonavir-Doxycycline, and Azithromycin-Hydroxychloroquine in Patients with Diagnosed Mild to Moderate COVID-19 Disease " that you submitted to Biochemistry Research International.

We are in the final stages of checking your manuscript and, in order for us to consider your manuscript, you will need to improve the language of the article. You can either ask a native English speaker to edit the manuscript for you, or use an editing service such as [Editage](#). You can find additional ones on our [author services page](#).

Please also consider revising your first sentence in the abstract 'The absence of a vaccine and effective treatment for COVID-19 with proper safety measurement remains the most significant obstacle' to reflect recent updates to vaccinations.

Please provide an updated manuscript by doing the changes to proceed further.

Best Regards,
Rajalakshmi.

Rajalakshmi Thanigaikumar

Editorial Quality Assurance

rajalakshmi.thanigaikumar@hindawi.com

Hindawi

Hindawi.com | [Twitter](#) | [Facebook](#) | [LinkedIn](#) | [YouTube](#)

PURWATI PURWATI <purwati@fk.unair.ac.id>

23 Desember 2020 11.12

Kepada: andang miatmoko <andang-m@ff.unair.ac.id>

Ini pak reviewan paling terakhirnya

[Kutipan teks disembunyikan]

PURWATI PURWATI <purwati@fk.unair.ac.id>
Kepada: Rajalakshmi ThanigaiKumar <rajalakshmi.thanigaikumar@hindawi.com>

23 Desember 2020 14.30

Dear Rajalakshmi,

Thank you for your email.

We will improve the language of the article and send to you the revised manuscript very soon.

May I ask a letter stating that our manuscript is considered for acceptance and publication in this journal? Thank you very much in advance.

Warm regards,

Purwati

[Kutipan teks disembunyikan]

Rajalakshmi ThanigaiKumar <rajalakshmi.thanigaikumar@hindawi.com>
Kepada: PURWATI PURWATI <purwati@fk.unair.ac.id>

23 Desember 2020 19.48

Dear PURWATI,

Please be informed that you will be receiving an email regarding the acceptance of the article only after the acceptance.

Best Regards,

Rajalakshmi.

Rajalakshmi Thanigaikumar

Editorial Quality Assurance

rajalakshmi.thanigaikumar@hindawi.com



Hindawi

Hindawi.com | [Twitter](#) | [Facebook](#) | [LinkedIn](#) | [YouTube](#)

[Kutipan teks disembunyikan]

Rajalakshmi ThanigaiKumar <rajalakshmi.thanigaikumar@hindawi.com>
Kepada: PURWATI PURWATI <purwati@fk.unair.ac.id>

28 Desember 2020 23.35

Dear PURWATI,

Please be informed that you will be receiving an email regarding the acceptance of the article only after the acceptance.

Best Regards,

Rajalakshmi.

Rajalakshmi Thanigaikumar

Editorial Quality Assurance

rajalakshmi.thanigaikumar@hindawi.comHindawi.com | [Twitter](#) | [Facebook](#) | [LinkedIn](#) | [YouTube](#)

[Kutipan teks disembunyikan]

PURWATI PURWATI <purwati@fk.unair.ac.id>
Kepada: Rajalakshmi ThanigaiKumar <rajalakshmi.thanigaikumar@hindawi.com>

17 Desember 2020 01.46

Dear Editor,

We are still on proofreading the manuscript and soon we will update you about the revised manuscript. Many thanks

[Kutipan teks disembunyikan]

Rajalakshmi ThanigaiKumar <rajalakshmi.thanigaikumar@hindawi.com>
Kepada: PURWATI PURWATI <purwati@fk.unair.ac.id>

29 Desember 2020 10.10

Dear PURWATI,

Thank you for your reply and information.
Please provide the manuscript once you are done.Best Regards,
Rajalakshmi.

Rajalakshmi Thanigaikumar

Editorial Quality Assurance

rajalakshmi.thanigaikumar@hindawi.comHindawi.com | [Twitter](#) | [Facebook](#) | [LinkedIn](#) | [YouTube](#)

[Kutipan teks disembunyikan]

PURWATI PURWATI <purwati@fk.unair.ac.id>
Kepada: Rajalakshmi ThanigaiKumar <rajalakshmi.thanigaikumar@hindawi.com>

30 Desember 2020 11.14

Dear Rajalakshmi,

Please kindly find the attachment file below for the revised manuscript after editing and proofreading by our native English speaker. We have made corrections for the first sentence in the abstract as marked with bold.

We also attach a certificate of editing from Colledge and Associates as confirmation of proof-reading services for your consideration.
Thank you in advance.

Warm regards,
Purwati

[Kutipan teks disembunyikan]

2 lampiran



Certificate of Editing Andang Miatmoko Biochemistry Research International 29-12-20.pdf

188K



A Randomized, Double-Blind Multi-center Clinical Study for Comparing the Efficacy and Safety of Drug Combination Proofread draft No.2 29-12-2020.docx

253K

Rajalakshmi ThanigaiKumar <rajalakshmi.thanigaikumar@hindawi.com>
Kepada: PURWATI PURWATI <purwati@fk.unair.ac.id>

31 Desember 2020 15.58

Dear PURWATI,

Thank you for your email.

Best Regards,
Rajalakshmi.

Rajalakshmi Thanigaikumar

Editorial Quality Assurance

rajalakshmi.thanigaikumar@hindawi.com



Hindawi

Hindawi.com | [Twitter](#) | [Facebook](#) | [LinkedIn](#) | [YouTube](#)

[Kutipan teks disembunyikan]

Colledge & Associates

50 Lewis Street
Derby
DE23 8BX
simondcolledge@gmail.com
<https://simondcolledge.wixsite.com/proofreading>
29th. December 2020

Catherine Farrell,
Editorial Production Editor,
Biochemistry Research International,
Hindawi Limited,
Adam House, Third Floor,
1 Fitzroy Square,
London W1T 5HF.

Subject: Confirmation of proof-reading services

Dear Ms. Farrell,

This letter serves to confirm that the manuscript entitled: "A Randomized, Double-Blind, Multi-center Clinical Study Comparing the Efficacy and Safety of a Drug Combination of Lopinavir/Ritonavir-Azithromycin, Lopinavir/Ritonavir-Doxycycline, and Azithromycin-Hydroxychloroquine for Patients Diagnosed with Mild to Moderate COVID-19 Infections", authored by Andang Miatmokoet al. has been subjected to proofreading and editing by Colledge & Associates.

In the event you require further information regarding this matter, please do not hesitate to contact our office. My colleagues will be pleased to answer any questions you may have.

Yours sincerely,

Simon Colledge

**FOUNDING DIRECTOR
COLLEDGE AND ASSOCIATES**

A Randomized, Double-Blind, Multi-center Clinical Study Comparing the Efficacy and Safety of a Drug Combination of Lopinavir/Ritonavir-Azithromycin, Lopinavir/Ritonavir-Doxycycline, and Azithromycin-Hydroxychloroquine for Patients Diagnosed with Mild to Moderate COVID-19 Infections

Purwati^{1,2*}, Budiono², Brian Eka Rachman³, Yulistiani^{3,4}, Andang Miatmoko^{1,3}, Nasronudin⁴, Soroy Lardo⁵, Yongki Iswandi Purnama⁵, Mafidhatul Laely⁶, Ike Rochmad⁷, Taufik Ismail⁸, Sri Wulandari⁸, Dwi Setyawan³, Alfian Nur Rosyid⁴, Herley Windo Setiawan⁴, Prastuti Asta W⁴, Tri Pudy Asmarawati⁴, Erika Marfiani⁴, Shinta Karina Yuniati⁴, Muhammad Rabiul Fuadi⁴, Pepy Dwi Endraswari⁴, Purwaningsih⁴, Eryk Hendrianto¹, Deya Karsari¹, Aristika Dinaryanti¹, Nora Ertanti¹, Igo Syaiful Ihsan¹, Disca Sandyakala Purnama¹, Yuni Indrayani¹

Affiliations

¹ Stem Cell Research and Development Center, Airlangga University, Campus C UNAIR Mulyorejo, Mulyosari, Surabaya, 60115, Indonesia.

² Faculty of Vocational Studies, Airlangga University, Campus B UNAIR, Jl. Dharmawangsa Dalam Selatan, Gubeng, Surabaya, 60286, Indonesia.

³ Faculty of Pharmacy, Airlangga University. Nanizar Zaman Joenoes Building, Campus C UNAIR Mulyorejo, Mulyosari, Surabaya. 60115, Indonesia.

⁴ Airlangga University Hospital, Campus C UNAIR Mulyorejo, Mulyosari, Surabaya, 60115, Indonesia

⁵ Gatot Soebroto Army Hospital, Jl. Abdul Rahman Saleh, Senen, Jakarta, 10410, Indonesia.

⁶ Covid-19 Isolation Center, Lamongan, Indonesia.

⁷ Dustira Hospital, Jl. Dustira, Baros, Cimahi Tengah, Cimahi, 40521, Indonesia.

⁸ Polri Hospital, Jl. Raya Bogor, Kramat Jati, Jakarta, 13510, Indonesia.

*Correspondence: Purwati@fk.unair.ac.id

Abstract

Background: At the present time, COVID-19 vaccines are at the testing stage and an effective treatment for COVID-19 incorporating appropriate safety measures remains the most significant obstacle to be overcome. A strategic countermeasure is, therefore, urgently required.

Aims: This study aims to evaluate the efficacy and safety of a combination of Lopinavir/Ritonavir-Azithromycin, Lopinavir/Ritonavir-Doxycycline, and Azithromycin-Hydrochloroquine used to treat patients with mild to moderate COVID-19 infections.

Setting and Design: This study was conducted at four different clinical study sites in Indonesia. The subjects gave informed consent for their participation and were confirmed as being COVID-19 positive by means of an RT-PCR test. The present study constituted a randomized, double-blind, and multicenter clinical study of patients diagnosed with mild to moderate COVID-19 infection.

Materials and Methods: Six treatment groups participated in this study: a Control group administered with a 500 mg dose of Azithromycin; Group A which received a 200/50 mg dose of Lopinavir/Ritonavir and 500 mgs of Azithromycin; Group B treated with a 200/50 mg dose of Lopinavir/Ritonavir and 200 mgs of Doxycycline; Group C administered with 200 mg of Hydroxychloroquine and 500 mg of Azithromycin, Group D which received a 400/100 mg dose of Lopinavir/Ritonavir and 500 mgs of Azithromycin; and Group E treated with a 400/100 mg dose of Lopinavir/Ritonavir and 200 mgs of Doxycycline.

Results: 754 subjects participated in this study, 694 patients (92.4%) who presented mild symptoms, and 57 patients (7.6%) classified as suffering from a moderate case of COVID-19. On the third day after treatment, 91.7%–99.2% of the subjects in groups A-E were confirmed negative by a PCR swab test compared to 26.9% in the Control group. Observation of all groups which experienced a significant decrease in virus load between day 1 and day 7 was undertaken. Other markers, such as CRP and IL-

6, were significantly lower in all treatment groups ($p < 0.05$ and $p < 0.0001$) compared with the Control group. Furthermore, IL-10 and TNF- α levels were significantly elevated in all treatment groups ($p < 0.0001$). The administration of Azithromycin to the Control group increased CRP and IL-6 levels, while reducing IL-10 and TNF- α on day 7 ($p < 0.0001$) compared with day 1. Decreases in ALT and AST levels were observed in all groups ($p < 0.0001$). There was an increase in creatinine in the serum level of the Control, C, D, and E and groups ($p < 0.05$), whereas the BUN level was elevated in all groups ($p < 0.0001$).

Conclusions: The study findings suggest that the administering of Lopinavir/Ritonavir–Doxycycline, Lopinavir/Ritonavir–Azithromycin and Hydroxychloroquine–Azithromycin as a dual drug combination produced a significantly rapid PCR conversion rate to negative in three-day treatment of mild to moderate COVID-19 cases. Further studies should involve observation of older patients with severe clinical symptoms in order to collate significant amounts of demographic data.

Keywords: clinical study, COVID-19, Lopinavir/Ritonavir, Azithromycin, Hydroxychloroquine, Doxycycline

INTRODUCTION

Since late 2019, a global campaign has been waged against the Corona 2019 (COVID-19) pandemic caused by the Severe Acute Respiratory Syndrome (SARS-CoV-2) virus which has infected 70.4 million people and caused 1,599,704 deaths worldwide.¹ Various initiatives have been undertaken in an attempt to eradicate the pandemic. However, to date, all efforts to halt the transmission and spread of COVID-19 have proved unsuccessful.

Several studies have reported that the majority of individuals (80%) infected with COVID-19 have presented mild to moderate symptoms.^{2,3,4} Indonesia is densely populated with 270 million inhabitants, the fourth-largest national population in the world. Consequently, the ongoing pandemic has significantly impacted the country in various sectors, including; economy, education, and health (source: <http://www.covid19.gov.id>). The majority of COVID-19 patients in Indonesia fall within productive age ranges, with an average isolation period of between 10 and 14 days, factors which have had a significant negative effect on the economic sector. On the other hand, approximately 35% of individuals falling within the country's productive age range live with their parents who are, consequently, identified as a high-risk group in relation to COVID-19 (source: Statistics Indonesia. <http://www.bps.go.id>). Therefore, proactive initiatives are required to facilitate the prompt social re-integration of those COVID-19 patients presenting mild and moderate symptoms.

Experts around the world have been working unstintingly to find an effective cure for COVID-19. Various drugs such as Azithromycin.⁶ Hydroxychloroquine.^{6,7} Lopinavir/Ritonavir.⁸ Remdesivir.⁸ Homoringtonine.⁸ and Emetine⁸ have been reported as demonstrating anti-viral potential during pre-clinical trials. Most represent newly-determined indicative uses of previous drug regimens. In Indonesia, researchers have identified several drugs such as Lopinavir/Ritonavir, Azithromycin, Doxycycline, and Hydroxychloroquine as potentially having curative effects against COVID-19 infection. In a previous study undertaken by the authors of this article, the CC50 values observed for an *in vitro* cytotoxicity assay on mesenchymal cells indicated that a combination of these drugs had a lower degree of toxicity compared to that of a single drug (unpublished data). The drug combination employed during the *in vitro* study proved effective at lowering the viral copy numbers in the Vero cells infected with SARS-CoV-2 which had been isolated from hospitalized patients at 72, 48, and, even, 24 hours after drug incubation (unpublished data). Moreover, the research in question also highlighted certain new combination drugs such as Lopinavir/Ritonavir; and Azithromycin, Lopinavir/Ritonavir and Doxycycline. Hydroxychloroquine and Azithromycin produced higher efficacy in inhibiting and eradicating the SARS-CoV-2 virus than their single form (unpublished data).

Several other recent studies have reported the efficacy and safety of some single drug⁵⁻⁸ or other drug combinations.^{13,14} However, many variations permeate their results. The present study evaluated the efficacy and safety of combinations of Lopinavir/Ritonavir and Azithromycin; Lopinavir/Ritonavir and Doxycycline; and Azithromycin and Hydroxychloroquine for patients suffering from mild to moderate COVID-19 who are undergoing treatment not involving the use of a ventilator.

METHODS

Study Conduct

This study constituted a multi-center, double-blind, and randomized controlled clinical trial (RCT) conducted between July and August 2020 at four research sites in Indonesia. The Ethics Committee granted ethical approval for all centers conducting clinical trial protocols (Persetujuan Pelaksanaan Uji Klinis, PPUK) No. PP.01.01.1.3.07.20.06 issued by the Indonesian Food and Drugs Administration (Badan Pengawas Obat dan Makanan Republik Indonesia) with an additional letter of approval from the National Institute of Health Research Development – Indonesian Ministry of Health (Balitbangkes Kementerian Kesehatan RI) and ethical approval No. 159/KEP/2020 issued by the Ethics Committee of Universitas Airlangga Hospital (RS UNAIR).

Research Population

For the purposes of this study, 1,045 subjects from four study sites, namely; Universitas Airlangga Hospital (RSUA, Surabaya); Dustira Hospital-Bandung; COVID-19 Isolation Center-Lamongan; and POLRI Hospital-Jakarta were initially assessed for eligibility before being screened and enrolled in accordance with the inclusion criteria of being male or female adults over the age of 18. The screening process produced 754 eligible subjects who were further randomized into six groups for the purposes of the intervention study as shown in Figure 1. The subjects registering a positive result on the COVID-19 PCR swab test presented mild, moderate, or severe symptoms. Those individuals willing to give informed consent prior to the study were then admitted as patients in one of the closest available hospitals or isolation centers. The exclusion criteria applied to the research subjects comprised: pregnant or breastfeeding mothers, individuals with severe liver disorders (indicated by increases in transaminases levels three times or more in excess of the normal range), impaired renal functions (indicated by decreases in creatinine clearance of less than 60 mL/minute), arrhythmia, and/or a compromised potassium/magnesium balance. Moreover, individuals receiving conventional plasma therapy and/or anti-IL-6 therapy; who experienced QT prolongation when QTc >60 ms, or QTc >500 ms with a narrow QRS, or QTc ³550 ms with wide QRS occurred during treatment; or who demonstrated proven resistance to one of the combinations of antibiotics studied, drug allergy vents, and adverse events due to the administration of other drugs were excluded from the study (as were those who discontinued their participation).

Randomization and Intervention

The subjects signed an informed consent form confirming their assent to participate in the study, after which they received the same treatment based on their clinical conditions. Randomized subjects were assigned to one of six treatment groups. The Control group was treated in accordance with the standard of care (SoC), including the administering of 500 mg Azithromycin once a day, supplements, and other drugs intended to address clinical symptoms. Group A consisted of subjects treated with a combination of 200/50 mg Lopinavir/Ritonavir twice a day and 500 mg Azithromycin once a day. Group B included subjects treated with a combination of 200/50 mg Lopinavir/Ritonavir and 100 mg Doxycycline twice a day. Group C contained subjects who received 200 mg Hydroxychloroquine twice a day and 500 mg Azithromycin once a day. Groups D and E were similar to Groups A and B, although their subjects

received a higher dose of 400/100 mg Lopinavir/Ritonavir twice a day. All groups also received supportive symptom-based treatments.

Study Evaluation: schedule of treatments and evaluation of study endpoints

The subjects were administered drugs, received supportive treatment and underwent physical health monitoring for 7-14 days to evaluate the study. Moreover, the assessed clinical signs were used to assess drug efficacy. An evaluation drawing on a combination of physical examination, clinical radiology, laboratory parameters, and RT-PCR for viral load was also conducted. Any adverse events, serious or otherwise, occurring during the study period were recorded.

The primary objectives of this study were to measure the efficacy of the drug combinations Lopinavir/Ritonavir and Azithromycin; Lopinavir/Ritonavir and Doxycycline; and Hydroxychloroquine and Azithromycin in improving the clinical outcomes of those COVID-19 patients hospitalized with mild and moderate symptoms. The clinical outcome parameters consisted of improvements in such physical functions as: maintaining optimum body temperature ($<37.5^{\circ}\text{C}$); respiratory rate (≤ 20 times per minute without the use of auxiliary respiratory muscles); oxygen saturation/SpO₂ ($>95\%$ without provision of supplemental oxygen); and hemodynamic stability (mean arterial pressure/MAP >65 mmHg). Moreover, the decrease in mortality rate was noted to establish the efficacy of drug combination therapy.

The secondary efficacy endpoint was to determine the safety of those drug combinations administered during the study which enhanced the clinical outcomes of COVID-19 patients with mild to moderate symptoms. It also evaluated patient complaints or discomfort, including; fever, coughing, breathlessness, sniffles, a sore throat, and other symptoms. Observations were also made of lung X-rays, clinical hematology test results, and cytokine levels,; the latter of which were analyzed for IL-2, IL-6, IL-10 and TNF- α by means of a sandwich ELISA method including the use of BT-Labs reagent kits Cat. No. E0094Hu, Cat. No. E0090Hu, Cat. No. E0102Hu, and Cat. No. E0082Hu purchased from the Bioassay-Technology Laboratory, China. The viral load was analyzed through Quantitative Real-Time Polymerase Chain Reaction (qRT-PCR), all assays of which were performed using an Applied Biosystem (AP) 7500 fast real time PCR system (Enigma, Applied Biosystem Foster city, CA, USA), with Allplex 2019-nCoV assay PCR reagent (Cat. No. RP10250X, Seegene, South Korea), and a Tiangen extraction kit (Cat. No. DP315-T8, Beijing, China). Viral load analysis was undertaken by first measuring the positive control virus concentration, cycle threshold (Ct) values, with a Qubit Fluorometer (Thermo Fisher Scientific, USA). The positive control was an Allplex 2019-nCoV assay kit. The Ct value was converted into copy viral DNA/ μl by plotting it as a linearity curve prepared at 8 concentrations.

Statistical Analysis

The 754 subjects were randomized into seven groups constituting six treatment groups and one Control group whose members received SoC. The primary efficacy data was analyzed through head-to-head SoC comparison of treatment groups by means of statistical analysis. Despite there being more than 30 patients in each group, the numerical data (ratio or interval) was further analyzed for normal distribution through the use of a Kolmogorov Smirnov test. If the data distribution was normal (p value ≥ 0.05), it was further subjected to an analysis of variance (ANOVA) and a Least Square Difference multiple comparison test. However, the data distribution in this study was not normal, leading to further analysis by the administering of Kruskal Wallis and Mann-Whitney multiple comparison tests. The resulting categorical data was evaluated using a Chi-Square test. Moreover, the study of secondary efficacy data used for pre- and post-study evaluation of clinical outcome indicators included lung x-rays, laboratory results, and viral load tests.

RESULTS

Patient Demographic

Of the 1,045 study subjects, 754 were enrolled according to the eligibility criteria shown in Figure 1. The 119 control group members received a single dose of Azithromycin. The 128 Group A patients were administered with 200/50 mg Lopinavir/Ritonavir + 500 mg Azithromycin. The 124 Group B patients received 200/50 mg Lopinavir/Ritonavir + 100 mg Doxycycline. The 123 Group C patients were given a combination of 200 mg Hydroxychloroquine + 500 mg Azithromycin. The 131 group D patients were treated with a combination of 400/100mg Lopinavir/Ritonavir + 500 mg Azithromycin. The medication administered to 129 patients consisted of a combination of 400/100 mg Lopinavir/Ritonavir + 100 mg Doxycycline. Two patients of Group C experienced adverse events during the study and deteriorated clinically causing the researchers to exclude them from further participation in the study. Furthermore, a Group D patient suffered from severe nausea and vomiting, resulting in immediate termination of the treatment and the removal of that individual from the study.




Figure 1. Patient’s clinical study disposition algorithm for comparing the efficacy of both Lopinavir/Ritonavir and Azithromycin, Lopinavir/Ritonavir and Doxycycline and Hydroxychloroquine and Azithromycin drug combinations in improving clinical outcomes of COVID-19 patients hospitalized with mild and moderate symptoms. Control group: 1 x 500

mg Azithromycin per day; Group A: 2 x 200/50 mg Lopinavir/Ritonavir + 1 x 500 mg Azithromycin per day; Group B: 2 x 200/50 mg Lopinavir/Ritonavir + 2 x 100 mg Doxycycline per day; Group C: 2 x 100 mg Hydroxychloroquine + 1 x 500 mg Azithromycin per day; Group D: 2 x 400/100 mg Lopinavir/Ritonavir + 1 x 500mg Azithromycin per day; Group E: 2 x 400/100 mg Lopinavir/Ritonavir + 2 x 100 mg Doxycycline per day.

Table 1. The baseline physical characteristics and clinical laboratory data of enrolled subjects who completed treatment during the study

	Total (n=751)	Control	A	B	C	D	E	p-value
Disease severity*								
Mild, n (%)		115 (96.6)	120 (93.8)	113 (91.1)	113 (93.4)	117 (90.0)	116 (89.9)	0.303
Moderate, n (%)		4 (3.4)	8 (6.3)	11 (8.9)	8 (6.6)	13 (10.0)	13 (10.1)	
Gender**								
Males	716 (95.3)	113 (95.0)	123 (96.1)	119 (96.0)	118 (97.5)	119 (91.5)	124 (96.1)	
Females	35 (4.7)	6 (5.0)	5 (3.9)	5 (4.0)	3 (2.5)	11 (8.5)	5 (3.9)	0.305
Age (in years)								
Median		37 [#]	37	37 [#]	36 [#]	37	37 [#]	0.105
Minimum		23	32	26	32	21	20	
Maximum		55	49	49	51	55	45	
Laboratory examination								
Median AST (U/L, minimum-maximum)								
		27 (13 - 69)	25 (12 - 78)	26 (12 - 78)	25 (5 - 68)	26 (13 - 65)	26 (13 - 213)	0.159
Median ALT (U/L, minimum-maximum)								
		34 (12 - 144)	32 (16 - 142)	33 (3 - 106)	31 (14 - 141)	36 (11 - 116)	35 (7 - 337)	0.317
Median creatinine serum (mg/dL, minimum-maximum)								
		0.96±0.13	0.94 (0.68 - 1.34)	0.96±0.12	0.95 (0.77 - 1.51)	0.98±0.50	0.98±0.12	0.712
BUN level (mg/dL)								
		10.7±2.2	11.3±1.8	11.1 (6.4 - 15.8)	11.2 (7.2 - 18.6)	11.1±2.3	11.1±2.1	
C reactive protein (CRP)								
		2.0 (0.1 - 69.1)	1.5 (0.1 - 35.2)	1.0 (0.1 - 32.4)	1.5 (0.1 - 43.7)	1.0 (0.0 - 77.3)	1.2 (0.1 - 65.1)	0.026
D-Dimer								
		203 (99 - 1,085)	166.5 (73 - 776)	177 (84 - 981)	176 (63 - 18,460)	191 (75 - 4,474)	180 (53 - 2,393)	0.078

* $\chi^2 = 6.031$; ** $\chi^2 = 3.952$; [#]significant difference from Group D; Control group: 1 x 500 mg Azithromycin per day; Group A: 2 x 200/50 mg Lopinavir/Ritonavir + 1 x 500mg Azithromycin per day; Group B: 2 x 200/50 mg Lopinavir/Ritonavir + 2 x 100mg Doxycycline per day; Group C: 2 x 100 mg Hydroxychloroquine + 1 x 500 mg Azithromycin per day; Group D: 2 x 400/100 mg Lopinavir/Ritonavir + 1 x 500 mg Azithromycin per day; Group E: 2 x 400/100 mg Lopinavir/Ritonavir + 2 x 100 mg Doxycycline per day; AST: aspartate aminotransferase serum; ALT: alanine aminotransferase serum; BUN: blood urea nitrogen; D-dimer: fibrin degradation fragment.

The evaluation of the clinical efficacy of drug combination therapy for COVID-19

Of the 751 study subjects contained in Table 1, 694 (92.4%) suffered from mild disease, while 57 (7.6%) presented moderate symptoms. The analysis focused only on the mild symptom group in order to avoid bias. 716 of the research subjects were male (95.3%), while females accounted for only 35 (4.7%). Gender was evenly distributed across all treatment groups as confirmed by the Chi-square test results which showed no significant difference ($p > 0.05$). The age range of participants enrolled in this study was between 20 and 55, with a median age of 36-37. A Mann Whitney study indicated a substantial difference between the Control and D group and the Control and Groups B, C and E;

however, they were in a closed range. The laboratory data results showed that the AST, ALT, serum creatinine, BUN, CRP, and D-dimer values were relatively equal in the Control and A-E groups.

Clinical improvement was assessed on the basis of several symptoms such as fever, sore throat, cough, cold/sniffle, inability to breathe, chest pains/shortness of breath, and diarrhea. On day 3, a number of participants continued to experience clinical discomfort, namely; 22 patients in the Control group (18.5%), and 5 subjects (3.9%), 9 subjects (7.3%), 11 subjects (9.1%), 12 subjects (9.2%), and 6 subjects (4.7%) respectively in Groups A, B, C, D, and E. According to this data, all forms of discomfort had been relieved on the fourth day of treatment.

Table 2. Analysis of laboratory data profiles of D-dimer, CRP level, interleukins and TNF- α of subjects in the control group and group A-E on day 1 and day 7 during treatment

Group	Control	A	B	C	D	E	p-value
Median level of D-Dimer (ng/mL FEU, minimum-maximum)							
Day-1	203 (99 – 1,085)	166.5 (73 – 776)	177 (0 – 981)	176 (63 – 18,460)	191 (75 – 4,474)	180 (53 – 2,393)	0.078
Day-7	169 (70 – 1,309)	158 (66 – 481)	152 (66 – 1,156)	160 (56 – 485)	173 (68 – 1,842)	161 (60 – 819)	0.549
CRP level (mg/L. minimum-maximum)							
Day-1	2.0 (0.1 – 69.1)	1.5 (0.1 – 35.2)	1.0 (0.1 – 32.4)	1.5 (0.1 – 43.7)	1.0 (0.0 – 77.3)	1.2 (0.1 – 65.1)	0.026
Day-7	0.7 (0.0 – 14.2)	0.6 (0.1 – 41.5)	0.6 (0.1 – 24.2)	0.6 (0.1 – 44.4)	0.6 (0.1 – 18.1)	0.8 (0.1 – 34.5)	0.039
IL-6 level (ng/mL, minimum-maximum)							
Day-1	167.9 (7.8 – 500.4)	191.0 (10.2 – 1,348.9)	183.2 (25.8 – 2,934.9)	180.4 (13.2 – 22,022.3)	194.2 (15.7 – 1,452.2)	190.7 (32.5 – 1,348.9)	<0.0001
Day-7	186.7* (18.3 – 2,432.9)	146.9* (0.2 – 407.1)	145.8* (19.8 – 1,753.9)	145.5* (6.3 – 2,940.0)	170.1* (0.4 – 820.2)	144.2* (3.5 – 476.7)	<0.0001
IL-10 level (pg/mL. minimum-maximum)							
Day-1	141.7 (53.7 – 1,702.9)	82.1 (35.5 – 342.5)	89.3 (35.5 – 404.1)	86.9 (30.9 – 388.8)	92.1 (32.7 – 408.1)	76.0 (39.3 – 319.9)	<0.0001
Day-7	105.9* (36.8 – 396.3)	128.6* (45.1 – 1,190.9)	142.0* (45.9 – 2,132.9)	144.8* (48.0 – 2,132.9)	145.7* (51.5 – 740.0)	147.2* (62.4 – 586.0)	<0.0001
Plasma level of TNF-α (pg/mL. minimum-maximum)							
Day-1	149.3 (5.2 – 821.0)	168.5 (49.9 – 2,316.7)	176.6 (56.0 – 872.2)	165.1 (52.9 – 1,185.5)	171.5 (47.1 – 1,026.4)	197.7 (59.4 – 808.6)	<0.0001
Day-7	179.0* (26.0 – 1,152.2)	137.9* (28.1 – 622.0)	143.8* (36.3 – 641.7)	138.6* (31.7 – 631.8)	142.6* (1.3 – 593.4)	130.8* (37.4 – 380.9)	<0.0001

Control group: 1 x 500 mg Azithromycin per day; Group A: 2 x 200/50 mg Lopinavir/Ritonavir + 1 x 500 mg Azithromycin per day; Group B: 2 x 200/50 mg Lopinavir/Ritonavir + 2 x 100 mg Doxycycline per day; Group C: 2 x 100 mg Hydroxychloroquine + 1 x 500 mg Azithromycin per day ; Group D: 2 x 400/100 mg Lopinavir/Ritonavir + 1 x 500 mg Azithromycin per day; Group E: 2 x 400/100 mg Lopinavir/Ritonavir + 2 x 100 mg Doxycycline per day; IL-6: Interleukin-6; IL-10: Interleukin-10; TNF- α : Tumor necrosis factor- α ; *p=0.0001 compared with day-1

A report was produced regarding the increase in the D-Dimer value related to a poor prognosis, resulting in thrombosis, bleeding, and mortality. This research, therefore, contains an analysis of D-Dimer. Based on the data contained in Table 2, a deterioration in the D-Dimer rate occurred in all post-therapy groups. No significant difference exists between the Control group and the drug treatment group. This study also evaluated the CRP rate. The data contained in Table 2 indicates that the CRP value of the Control group and treatment groups A-E ranged from 1.0-2.0 in D-1 before experiencing a significant decrease (P <0.0001) to a value of <1.0 in D-7 due to the administering of medication.

To analyze the effectiveness, cytokine levels in the blood including IL-6, IL-10, and TNF- α were analyzed on days 1 and 7. On initial examination of the subjects, most of the IL-6 rate had

increased compared to the normal rate in the range of values 7.8 – 22,022.3 pg/ml with a cut-off point of 9.16 pg/ml in the median value as shown in Table 2. After administering a combination of drug therapies for seven days, an improvement in the IL-6 rate was recorded from a median value of 167.9 ng/ml to one of 186.7 ng/ml ($p < 0.0001$). In Groups A-E, a decrease in the IL-6 rate occurred. In Group A, the median value of 191.0 ng/ml became one of 146.9 ng/ml ($p < 0.0001$); in Group B, the median value of 183.2 ng/ml fell to 145.8 ng/ml ($p < 0.0001$); in Group C the median value decreased from 180.4 ng/ml to 145.5 ng/ml, ($p < 0.0001$); in Group D the median value fell from 194.2 ng/ml to 170.1 ng/ml ($p < 0.0001$); and in Group E, there was a decrease in the median value from 190.7 ng/ml 144.2 ng/ml ($p < 0.0001$). These results indicated a significant difference ($p < 0.0001$) between the Control group and the A-E combination drug groups.

The Interleukin-10 (IL-10) rate was also monitored. IL-10 is an anti-inflammatory cytokine found in humans whose IL-10 gene encodes IL-10. In this research, there was a mild to moderate increase in IL-10 levels in subjects with a cut-off point of 25.66 pg/ml at the outset of the examination. IL-10 levels ranged from 30.9 to 1,702.9 pg/ml with median values as listed in Table 2. After seven days of therapy, the results showed that the SoC group demonstrated a reduced level of IL-10 from a median of 141.7 ng/ml to 105.9 ng/ml ($p < 0.0001$). In comparison, the treatment group recorded an increase in IL-10 levels. In Group A, there was a significant increase from a median value of 82.1 ng/ml to 128.6 ng/ml ($p < 0.0001$). In Group B, the IL-10 value increased from a median value of 89.3 ng/ml to 142.0 ng/ml ($p < 0.0001$), in Group C the median value increased from 86.9 ng/ml to 144.8 ng/ml ($p < 0.0001$), in Group D the median value 92.1 ng/ml became 145.7 ng/ml ($p < 0.0001$), and in Group E the median value increased from 76.0 ng/ml to 147.2 ng/ml ($p < 0.0001$). Based on these results, it can be concluded that a significant difference ($p < 0.0001$) existed between the Control and the A-E combination drug groups. IL-10 plays a role in preventing the occurrence of tissue injury. Consequently, the treatment group had significantly increased levels of the anti-inflammatory cytokines compared to those of the SoC group.

An initial examination of the research subjects indicated an improvement in TNF- α levels on the normal level with a minimum value (5.2 – 2,316.7) pg/ml, a cut-off point of 3.79 pg/ml, and the median value as shown in Table 2. Following the provision of therapy for seven days, the results showed that the Control group had experienced an increase from a median of 149.3 ng/ml to 179.0 ng/ml, ($p < 0.0001$). Meanwhile, there was a significant decrease in TNF- α levels ($p < 0.0001$) on the seventh day of therapy. Moreover, significant differences ($p < 0.0001$) were also found between the Control group and the combination drug A-E groups.




Figure 2. The RT-PCR analysis results of all subjects in the Control and treatment groups of A-E on day 3 (A) and day 7 (B) during the study period (***) $p < 0.0001$ compared with the Control). Control group: 1 x 500 mg Azithromycin per day; Group A: 2 x 200/50 mg Lopinavir/Ritonavir + 1 x 500 mg Azithromycin per day; Group B: 2 x 200/50 mg Lopinavir/Ritonavir + 2 x 100 mg Doxycycline per day; Group C: 2 x 100 mg Hydroxychloroquine + 1 x 500 mg Azithromycin per day; Group D: 2 x 400/100 mg Lopinavir/Ritonavir + 1 x 500 mg Azithromycin per day; Group E: 2 x 400/100 mg Lopinavir/Ritonavir + 2 x 100 mg Doxycycline per day.

The RT-PCR analysis on day 3 showed that 26.9% of subjects in the Control group returned a negative result. In contrast, the negative PCR results were in 91.7-99.2% of all the tested subjects observed in groups A-E. On the day 7, there was 31.1% increase in the control group and about 93.0-98.3% for groups A-E. A Chi-square analysis revealed a significant difference ($p < 0.0001$) between all tested and control groups on day 3 and day 7 of treatment, as presented in Figure 2.

Table 3. The results of the copy number of the virus of control and treatment groups were analyzed in subjects with mild severity and total subjects evaluated using qRT-PCR on treatment days 1, 3, and 7.

Period of Treatment	Control	A	B	C	D	E	p-value
<i>Copy virus number in subjects with mild severity</i>							
Day-1	193.2 (14.1 – 48,113.7)	67.0 (11.9 – 4,531.4)	73.2 (11.9 – 2,945.8)	173.3 (12.4 – 5,116.0)	828.8 (11.8 – 370,523.6)	588.4 (11.0 – 11,877.6)	
Day-3	49.9.0 (0.0 – 15,085.1)	0.0 (0.0 -120.6)	0.0 (0.0 -172.8)	0.0 (0.0 -617.9)	0.0 (0.0 – 1,341.9)	0.0 (0.0 – 1,547.8)	
Day-7	19.8 (0.0 – 1,445.6)	0.0 (0.0 – 3,191.4)	0.0 (0.0 – 66.7)	0.0 (0.0 – 100.7)	0.0 (0.0 – 114.8)	0.0 (0.0 – 148.3)	
<i>Copy number of virus in total subjects</i>							
Day-1	193.2 (14.1 – 48,113.7)	67.0 (11.9 – 4,531.4)	73.2 (11.9 – 2,945.8)	183.6 (12.4 – 5,116.0)	854.8 (11.8 – 370,523.6)	670.0 (11.0 – 11,877.6)	0.001
Day-3	45.4 (0.0 – 15,085.1)	0.0 (0.0 -120.6)	0.0 (0.0 -172.8)	0.0 (0.0 -617.9)	0.0 (0.0 – 2,900.6)	0.0 (0.0 – 1,547.8)	0.012
Day-7	19.8 (0.0 – 1,445.6)	0.0 (0.0 – 3,191.4)	0.0 (0.0 – 66.7)	0.0 (0.0 – 100.7)	0.0 (0.0 – 278.0)	0.0 (0.0 – 148.3)	0.039

Control group: 1 x 500 mg Azithromycin per day; Group A: 2 x 200/50 mg Lopinavir/Ritonavir + 1 x 500 mg Azithromycin per day; Group B: 2 x 200/50 mg Lopinavir/Ritonavir + 2 x 100 mg Doxycycline per day; Group C: 2 x 100 mg Hydroxychloroquine + 1 x 500 mg Azithromycin per day; Group D: 2 x 400/100 mg Lopinavir/Ritonavir + 1 x 500 mg Azithromycin per day; Group E: 2 x 400/100 mg Lopinavir/Ritonavir + 2 x 100 mg Doxycycline per day.

In addition to the qualitative analysis conducted, this research undertook quantitative analysis relating to the number of virus copies. There was a significant decrease in this from D-1, D-3, and D-7 in both the SoC and treatment groups. On the other hand, for Group E, which was given the usual Lopinavir/Ritonavir dose, experienced no significant decrease in D-3 or D-7. The pre-treatment virus copy inspection results showed that the descending order of groups was that of D, E, Control, C, B, and A. The Kruskal Wallis test result value was one of $p < 0.05$, indicating a significant pre-treatment difference in virus copies. The results of the statistical analysis of observations indicated a tendency for the number of virus copies to have decreased when observed on days 1, 3, and 7, with the median value of the number of virus copies being as listed in Table 3.

The evaluation of clinical safety and tolerability of drug combination therapy for COVID-19

Table 4. The adverse events observed in the research subjects during the study period

Adverse events	Number of subjects (n)						p-value	
	Control	A	B	C	D	E		
Nausea					1	1		
Vomiting					1			
Dizziness	2	1			1			
Pruritus	1							
Tachycardia	1	1	1	1	1			
Hearing loss		1						
Abdominal pain		1			1	1		
Otalgia				1				
Diarrhea					1			
Taste loss							1	
Number of patients with leukocytosis (platelet count >12,000 per μL), n(%)								
Day-1	4 (3.4)	4 (3.1)	4 (3.2)	4 (3.3)	3 (2.3)	5 (3.9)	0.543	
Day-7	1 (1.0)	0 (0.0)	2 (1.7)	1 (0.9)	1 (0.9)	2 (1.7)	0.891	
Number of patients with thrombocytopenia (platelet count <150,000 per μL), n(%)								
Day 1	2 (1.7)	0 (0.0)	1 (0.8)	0 (0.0)	0 (0.0)	3 (2.3)	0.331	
Day 7	1 (1.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	3 (2.6)	0.147	
Number of patients with lymphocytopenia (lymphocyte count <1,500 per μL), n (%)								
Day 1	6 (5.1)	6 (4.7)	12 (9.7)	10 (8.3)	12 (9.2)	10 (7.8)	0.559	
Day 7	2 (1.9)	3 (2.4)	11 (9.3)	7 (6.1)	5 (4.4)	7 (6.0)	0.102	
Number of patients with an increase of AST level, n(%)								
Day 1	>33 U/L	36 (30.5)	31 (24.4)	22 (17.7)	23 (19.0)	31 (23.8)	35 (27.1)	0.168
Day 7	>33 U/L	19 (18.1)	13 (10.2)	8 (6.8)	20 (17.4)	13 (11.4)	22 (19.0)	0.029
Number of patients with an increase of ALT level, n(%)								
Day 1	>50 U/L	27 (22.8)	27 (21.3)	22 (15.7)	19 (15.7)	34 (26.2)	35 (27.1)	0.185
Day 7	>50 U/L	21 (20.0)	19 (14.8)	12 (10.2)	21 (18.3)	14 (12.3)	21 (18.1)	0.270
Number of patients categorized according to serum creatinine level, n(%)								
Day 1	>1.2 mg/dL	4 (3.4)	6 (4.8)	4 (3.2)	3 (2.5)	7 (5.4)	5 (3.9)	0.860
Day 7	>1.2 mg/dL	9 (8.6)	8 (6.3)	8 (6.8)	11 (9.6)	11 (9.6)	15 (12.9)	0.515
Median level of AST (U/L, min-max)								
Day 1		27 (13 - 69)	25 (12 - 78)	26 (12 - 78)	25 (5 - 68)	26 (13 - 65)	26 (13 - 213)	
Day 7		27 (17 - 49) *	22 (14 - 55) ***	24 (14 - 58) **	25 (6 - 92) *	25 (14 - 53) *	25 (16 - 73)*	<0.05*
Median level of ALT (U/L, min- max)								
Day 1		34 (12 - 144)	32 (16 - 142)	32 (3 - 106)	31 (14 - 141)	36 (11 - 116)	35 (7 - 337)	

Day 7	33 (16 - 106) ***	26 (12 - 140) ***	28 (2 - 137) ***	35 (14 - 205) ***	32 (2 - 91)***	28 (8 - 128)***	<0.05*
Median level of creatinine serum (mg/dL, min- max)							
Day 1	0.95±0.12	0.93 (0.68 - 1.34)	0.96±0.12	0.95 (0.77 - 1.34)	0.97±0.14	0.97±0.13	
Day 7	0.99±0.16**	0.94 (0.67 - 1.37)	0.95±0.13	0.96 (0.71 - 1.31)*	1.02±0.16***	0.99±0.15**	<0.05*
BUN level (mg/dL)							
Day 1	10.7±2.2	11.3±1.8	11.1 (6.4 - 15.8)	11.2 (7.2 - 18.6)	11.1±2.3	11.3±2.1	
Day 7	11.6±2.5***	11.9±2.2***	11.7 (7.0 - 21.3) ***	12.0 (8.3 - 20.1)***	12.4±2.5***	13.0±2.6***	<0.05*

Control group: 1 x 500mg Azithromycin per day; Group A: 2 x 200/50mg Lopinavir/Ritonavir + 1 x 500mg Azithromycin per day; Group B: 2 x 200/50 mg Lopinavir/Ritonavir + 2 x 100 mg Doxycycline per day; Group C: 2 x 100 mg Hydroxychloroquine + 1 x 500 mg Azithromycin per day ; Group D: 2 x 400/100 mg Lopinavir/Ritonavir + 1 x 500mg Azithromycin per day; Group E: 2 x 400/100 mg Lopinavir/Ritonavir + 2 x 100 mg Doxycycline per day; AST: aspartate aminotransferase serum; ALT: alanine aminotransferase serum. Normally distributed data presented in mean ± SD was analyzed by means of a paired t-test, whereas the other data was analyzed using a Wilcoxon-signed rank test. *p<0.05 compared to day 1, **p=0.001 compared to day 1, ***p<0.0001 compared to day 1

As shown in Table 4, all the treatment groups participating in this study had experienced adverse events. Four Group C subjects complained of headaches, a rapid pulse rate (tachycardia), and pruritus (itchiness) lasting for two days during treatment. Similar symptoms were also observed in four Group A members who experienced headaches for a day, a rapid pulse rate lasting 15 minutes, impaired hearing for a day, and abdominal pain for 30 minutes. Only one Group B subject experienced rapid heartbeat for 15 minutes, while two Group C subjects complained of hearing problems for two days and a rapid heart rate for two hours. Moreover, six subjects experienced diarrhea for one day in addition to headache, nausea, vomiting, abdominal pain, and a rapid pulse rate for 15 minutes. In Group E, three subjects reported experiencing discomfort such as a bitter taste in the mouth, nausea, and abdominal pain for one day. Two Group C subjects dropped out of the study due to severe adverse conditions of a prolonged QT interval >60 ms and clinical failure. The individuals concerned should have started using a ventilator on day 4. Moreover, one Group D subject experienced severe nausea caused by double consumption of anti-tuberculosis drugs resulted in his/her withdrawal from the project.

According to the data in Table 4, 24 of the subjects had high leukocyte levels above 12,000 per μ L, although there was an improvement (a decrease in the number of leukocytes to within normal limits) on the seventh day. There was no significant difference between the Control group and the A-E drug treatment groups ($p=0.543$). Furthermore, six of the 751 research subjects experienced thrombocytopenia during D-1 therapy. This number was relatively unchanged on D-7, except in Group B which initially contained one person on D-1, subsequently becoming zero on D-7 following treatment. In general, patients did not have lymphocytopenia, with 90-95% of normal patients being on D-1. Only 6-12 of the 751 study subjects experienced lymphocytopenia during D-1 therapy, and this number decreased by half relative to D-7, except in Group B whose members received 200/50 mg of Lopinavir/Ritonavir and 500 mg of Azithromycin combination therapy. Of the 12 individuals on D-1, 11 moved on to D-7 therapy. Overall, there was no significant difference between the Control group and the A-E drug treatment groups.

The research results showed that between 17.7% and 30.5% of research subjects demonstrated high aspartate aminotransferase (AST) levels at D-1. Compared with the control group, the drug treatment group experienced significantly decreasing numbers of between 6.8% and 19.0% as a result of D-7 therapy. Furthermore, as shown in Table 3, SGOT levels decreased significantly between days 1 and 7 in all treatment groups. Furthermore, as many as 164 research sample subjects (21.9%) had pre-treatment alanine aminotransferase (ALT) levels above 50 U/L, with this number decreasing to 108 (15.5%) at D-7. Based on the Chi-square test results, no significant difference existed between treatment groups in terms of the number of subjects with ALT levels above 50 U/L either before

treatment or on the seventh day after treatment. However, there was an improvement in the liver condition, which was indicated by a significant reduction in ALT levels on day 7 of therapy ($p < 0.0001$) for both treatment and control groups. Based on these data, nearly a quarter of the total research samples had decreased liver function based on AST and ALT checkup before drug administration. After the 7th day, there was an improvement in liver function. Accordingly, there was no significant difference between AST and ALT in the treatment groups, both before treatment and the 7th day after treatment.

Furthermore, 29 patients in the study had pre-treatment serum creatinine levels above 1.2 mg/dL, a total which increased to 62 on D-7. The Chi-square test results indicated no significant difference post-treatment in serum creatinine above 1.2 mg/dL between treatment groups in both D-1 and D-7. Although a statistical increase in the median serum creatinine level occurred, it remained biologically safe. All study samples had BUN levels ≤ 43 mg/dL, which were still within normal limits in both D-1 and H-7. Paired t-test results showed an increase in BUN levels in all treatment groups. However, again, the levels continued to fall within normal limits.

DISCUSSION

In the present study, the efficacy and safety of drug combination therapies consisting of Lopinavir/Ritonavir, Azithromycin, Doxycycline, and Hydroxychloroquine was investigated in a randomized, double-blind clinical study design. Several parameters have been determined, including clinical signs, hematological laboratory data comprising blood count, D-Dimer, CRP, cytokines profiling, qualitative and quantitative PCR assays for the virus load to evaluate the efficacy of the drug combinations used in COVID-19 therapy. The safety aspect of the drugs was assessed by observation of clinical discomfort and liver-kidney function test results. The subjects in this study were reasonably distributed in age, ranging between 21-55 years, with the majority diagnosed with a mild case of COVID-19. However, the disease progression of COVID-19 increased the mortality rate. Moreover, the disease proved to be both highly contagious and promoting high-risk comorbidity. Therefore, curative action on mild COVID-19 cases constitutes an essential step in preventing the infection from spreading and worsening clinical conditions. Such action also has benefits in terms of reducing the period of self-isolation required for daily work stimulating economic growth.

Treatment groups A-E participating in this study showed improved PCR conversion results on day 3 when 92.9%-98.3% of subjects were confirmed as PCR negative. This figure differed significantly from that of the Control group which had been given Azithromycin ($p < 0.05$). This result supports previously reported non-randomized clinical trials that suggested a combination of several drugs was more effective compared to individual drugs¹⁵. However, only a particular type of medications was used to treat severe cases of COVID-19. However, the result of this study did not match that of the clinical trial conducted in China⁹. Moreover, the Chinese patients received Lopinavir/Ritonavir via nasogastric tube due to their inability to swallow. Other studies reported that for such cases, Lopinavir/Ritonavir would worsen the patient's condition.¹⁶

During the viral copy number or viral load measurement, subgroups other than mild COVID-19 were included since the high rate of recovery in this group enabled rapid positive PCR conversion. The comprehensive analysis showed a significant decrease in subjects with positive PCR for COVID-19 in groups A to E, which differed significantly from the Control group ($p < 0.0001$). This remarkable discovery revealed that treated groups whose drug combinations contain Azithromycin experienced rapid declining rates compared to non-Azithromycin groups (day 3 as against day 7). Azithromycin plays a role in rapidly decelerating the process of viral penetration of a cell and as an immune modulator agent in increasing the production of interferon types I and III.¹⁷ Moreover, Azithromycin could activate MDA-5, while RIG-1 genes regulated the viral presentation in cells.¹⁸ The unforeseen result of Group B was a consequence of administering a half dose of Lopinavir/Ritonavir compared to Group E which experienced a significant decline in viral load. The sub-analysis was applied to the group

containing Azithromycin combined with Hydroxychloroquine (Group C) and resulted in higher viral load declining rates than the group treated with Lopinavir/Ritonavir (Group A); 87% and 74.8%, respectively. This result was noteworthy since a previous study had reported that in mild and moderate COVID-19, a single dose of these drugs produced the opposite effect.¹⁰ Despite using the drug combination therapy, the present investigation involved a larger sample size and several study centers conducted evaluations.

Hyper-inflammatory responses in COVID-19 cases indicated a major decline in the patient's clinical condition. Moreover, the worsening condition was due to the elevation of pro-inflammatory cytokines levels, i.e. IL-6. Serologically, the IL-6 level increased in COVID-19 patients as their clinical symptoms worsened^{19,20}, together with the initial indicator of their cytokine level fluctuations²¹⁻²³. Other symptoms included an impaired coagulation predictor²⁴ and severe lung damage²⁵ necessitating emergency mechanical ventilation²⁶ and increasing COVID-19 patient mortality.²⁷ The present study revealed a significant decrease in IL-6 ($p < 0.0001$) on day 7 across all treatment groups (Groups A-E and the Control group). This inconsistency might be due to the role of SARS-CoV-2 in modulating the immune system. As previously reported, the level of IL-6 expression could be activated with other cytokines like TNF- α and IL-1 β ²⁸, as shown in the murine protein model of SARS-CoV-1. This protein has a high structural similarity to SARS-CoV-2 that N (nucleocapsid) protein directly influenced the secretion of IL-6 through NF- κ B.²⁹ The previous discovery was strongly supported by the relation between IL-6 serological level with viral load counts.³⁰ However, significant variation of IL-10 level was only observed in Groups A and B. Despite its full mechanism remaining unknown, a contradictory result of IL-10 measurement indicated more severity and a higher mortality rate in MERS³¹. The complete opposite is shown in SARS-CoV-1.³² The dynamic of IL-10 alteration rates indicates that, as an anti-inflammatory marker, the cytokines level fluctuates in respond to a high level of pro-inflammatory cytokine. Based on this theory, the cytokine level measurement in this study could not depict the dynamic changes during the COVID-19 infection since it had be taken twice during the treatments administered.

Another inflammation indicator used to predict worsening clinical condition in COVID-19 patients is the C-Reactive Protein (CRP) level.^{33,34} CRP levels decreased significantly on day 7 in all treated groups (Group A-E and the Control group) with a median level of 0.6-0.7 mg/dL which was lower than the cut-off value for high-risk patients (2.69 mg/dL). In this study, the decrease of CRP and D-dimer levels was measured on days 3 and 7. However, there were no significant differences with the Control group ($p > 0.05$) which was probably due to the anti-inflammation effect of Azithromycin and Doxycycline.³⁵

Due to the patient's pre-COVID-19 infection medical history, he/she often suffered liver damage as a direct result of the severity of treatment.^{36,37} The condition was worsened by the continued use of hepatotoxic medications such as Lopinavir/Ritonavir^{6,38}. In this study, a significant rise in the ALT level was observed only in Group C ($p < 0.05$), although no significant clinical effect ensued from the difference (31 mg/dL on day 1 to 35 mg/dL on day 7). Moreover, the prolonged QT interval represented a severe adverse event for hydroxychloroquine-based therapy such as was the case for one subject in Group C. The previous prediction had been based on a toxicity test of mesenchymal cells which reported that the CC₅₀ level used in drug combination therapies was lower than that of a single administration of each drug (unpublished data). A kidney function test revealed that the BUN level increased significantly ($p < 0.05$) in all treated groups (Groups A-E and the Control group), although it had no effect on the patient's clinical condition. However, there were no significant differences in any treatment groups other than the control group which suggests that every subject experienced different effects during treatments.

During the evaluation, the imbalanced proportional subject distribution and the inadequate analytical laboratory equipment employed at different research sites emerged as the significant

drawbacks of this study. Nevertheless, this did not reflect the current condition of hospitals in Indonesia. The broad range of patient symptoms and degree of severity of the disease should be further investigated to enhance current understanding of the benefits of drug combination therapies in relation to the contrasting severity of the disease in COVID-19 patients. The last drawback was due to the upper age limit of subjects being set at 55. This study did not demonstrate the nature of the efficacy of drug combination therapies and drug safety with regard to the geriatric age group.

CONCLUSION

The present study confirmed that the proposed combined therapies successfully accelerated the process of PCR negative conversion compared to the control group which had been administered with Azithromycin. Moreover, the inflammation rate decreased on day 7 of the study. Clinical test and liver-kidney function examination results confirmed that the proposed combination of drugs is safe for clinical use. Further studies must be conducted in the near future with older subjects presenting severe symptoms in order to obtain advanced demographic data.

DECLARATIONS

Ethics Statement

The researchers conducted the clinical trials across multi-center sites through collaboration between Universitas Airlangga, the Indonesian Intelligent Agency (BIN), and the Indonesian National Army (TNI AD). This study was conducted in strict accordance with the approved clinical trial protocols (PPUK) provided by BPOM (no. PP.01.01.1.3.07.20.06) with an additional letter of approval from the National Institute of Health Research Development – Indonesian Ministry of Health (Balitbangkes Kementerian Kesehatan RI) and ethical approval No 159/KEP/2020 issued by Ethics Committee of Universitas Airlangga Hospital (RS UNAIR) on June 23, 2020. The documents submitted to secure PPUK clearance can be found in the appendix entitled Supporting Documents 1 and 2.

Availability of data and material

Availability of data and materials.

Competing interests

The authors report no conflicts of interest arising from the content of this work.

Acknowledgements

The authors would like to express their gratitude to the Indonesian Intelligent Agency (BIN) as the primary sponsor of this research and collaboration with the Indonesian National Army (TNI AD). They would like to thank Universitas Airlangga for its invaluable support of the publication of the research and all the clinicians, medical and laboratory staff at various for their indispensable assistance to this study.

REFERENCES

1. World Health Organisation. 2020. WHO Coronavirus Disease (COVID-19) Dashboard. <https://covid19.who.int> accessed on December 14th, 2020 at 11.26.
2. Aylward Bruce and Liang Wannian. 2020. Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19). <https://www.who.int/docs/default-source/coronaviruse/who-china-joint-mission-on-covid-19-final-report.pdf> accessed on December 14th, 2020 at 11.26.
3. Marco Cascella, Michael Rajnik, Arturo Cuomo, Scott C. Dulebohn, Raffaella Di Napoli. 2020. Features, evaluation and Treatment of Coronavirus. Treasure Island (FL) : StatPearls Publishing. <https://www.ncbi.nlm.nih.gov/books/NBK554776/> accessed on December 14th, 2020 at 11.26.
4. Centers for Disease Control and Prevention. 2020. Clinical Care Guidance. <https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-guidance-management-patients.html> accessed on December 14th, 2020 at 11.26.
5. Liu Y. Zhang X. Qiao J. Gong R. You Q. Sun J. et al. A Controllable Inflammatory Response and Temporary Abnormal Coagulation in Moderate Disease of COVID-19 in Wuhan, China. *J Clin Med Res.* 2020;12(9):590-7.
6. Tanriverd IE. M CO. Yildirim BZ. EG UGC. Turan D. Cinarka H. et al. The use of hydroxychloroquine plus azithromycin and early hospital admission are beneficial in Covid-19 patients: Turkey experience with real-life data. *Turk J Med Sci.* 2020.
7. Yao X. Ye F. Zhang M. Cui C. Huang B. Niu P. et al. In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). *Clinical Infectious Diseases.* 2020;71(15):732-9.
8. Choy KT. Wong AY. Kaewpreedee P. Sia SF. Chen D. Hui KPY. et al. Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro. *Antiviral Res.* 2020;178:104786.
9. Cao B. Wang Y. Wen D. Liu W. Wang J. Fan G. et al. A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. *N Engl J Med.* 2020;382(19):1787-99.
10. Kim JW. Kim EJ. Kwon HH. Jung CY. Kim KC. Choe JY. et al. Lopinavir-ritonavir versus hydroxychloroquine for viral clearance and clinical improvement in patients with mild to moderate coronavirus disease 2019. *Korean J Intern Med.* 2020.
11. Lecronier M. Beurton A. Burrell S. Haudebourg L. Deleris R. Le Marec J. et al. Comparison of hydroxychloroquine, lopinavir/ritonavir, and standard of care in critically ill patients with SARS-CoV-2 pneumonia: an opportunistic retrospective analysis. *Crit Care.* 2020;24(1):418.
12. Li Y. Xie Z. Lin W. Cai W. Wen C. Guan Y. et al. Efficacy and Safety of Lopinavir/Ritonavir or Arbidol in Adult Patients with Mild/Moderate COVID-19: An Exploratory Randomized Controlled Trial. *Med (N Y).* 2020.
13. Huang YQ. Tang SQ. Xu XL. Zeng YM. He XQ. Li Y. et al. No Statistically Apparent Difference in Antiviral Effectiveness Observed Among Ribavirin Plus Interferon-Alpha, Lopinavir/Ritonavir Plus Interferon-Alpha, and Ribavirin Plus Lopinavir/Ritonavir Plus Interferon-Alpha in Patients With Mild to Moderate Coronavirus Disease 2019: Results of a Randomized, Open-Labeled Prospective Study. *Front Pharmacol.* 2020;11:1071.

14. Hung IF. Lung KC. Tso EY. Liu R. Chung TW. Chu MY. et al. Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. *Lancet*. 2020;395(10238):1695-704.
15. Gautret P. Lagier JC. Parola P. Hoang VT. Meddeb L. Mailhe M. et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. *Int J Antimicrob Agents*. 2020;56(1):105949.
16. Eljaaly K. Al-Tawfiq JA. Crushing lopinavir-ritonavir tablets may decrease the efficacy of therapy in COVID-19 patients. *Travel Med Infect Dis*. 2020:101749.
17. Li C. Zu S. Deng Y-Q. Li D. Parvatiyar K. Quanquin N. et al. Azithromycin Protects against Zika Virus Infection by Upregulating Virus-Induced Type I and III Interferon Responses. *Antimicrobial Agents and Chemotherapy*. 2019;63(12):e00394-19.
18. Menzel M. Akbarshahi H. Bjermer L. Uller L. Azithromycin induces anti-viral effects in cultured bronchial epithelial cells from COPD patients. *Sci Rep*. 2016;6:28698.
19. Coomes EA. Haghbayan H. Interleukin-6 in Covid-19: A systematic review and meta-analysis. *Rev Med Virol*. 2020:e2141.
20. Xu X. Yu MQ. Shen Q. Wang LZ. Yan RD. Zhang MY. et al. Analysis of inflammatory parameters and disease severity for 88 hospitalized COVID-19 patients in Wuhan, China. *Int J Med Sci*. 2020;17(13):2052-62.
21. Wang SF. Tseng SP. Yen CH. Yang JY. Tsao CH. Shen CW. et al. Antibody-dependent SARS coronavirus infection is mediated by antibodies against spike proteins. *Biochem Biophys Res Commun*. 2014;451(2):208-14.
22. Abbasifard M. Khorramdelazad H. The bio-mission of interleukin-6 in the pathogenesis of COVID-19: A brief look at potential therapeutic tactics. *Life Sci*. 2020;257:118097.
23. Wang C. Fei D. Li X. Zhao M. Yu K. IL-6 may be a good biomarker for earlier detection of COVID-19 progression. *Intensive Care Med*. 2020;46(7):1475-6.
24. Zhang D. Zhou X. Yan S. Tian R. Su L. Ding X. et al. Correlation between cytokines and coagulation-related parameters in patients with coronavirus disease 2019 admitted to ICU. *Clin Chim Acta*. 2020;510:47-53.
25. Chen LD. Zhang ZY. Wei XJ. Cai YQ. Yao WZ. Wang MH. et al. Association between cytokine profiles and lung injury in COVID-19 pneumonia. *Respir Res*. 2020;21(1):201.
26. Herold T. Jurinovic V. Arnreich C. Lipworth BJ. Hellmuth JC. von Bergwelt-Baildon M. et al. Elevated levels of IL-6 and CRP predict the need for mechanical ventilation in COVID-19. *J Allergy Clin Immunol*. 2020;146(1):128-36 e4.
27. Luo M. Liu J. Jiang W. Yue S. Liu H. Wei S. IL-6 and CD8+ T cell counts combined are an early predictor of in-hospital mortality of patients with COVID-19. *JCI Insight*. 2020;5(13).
28. Hunter CA. Jones SA. IL-6 as a keystone cytokine in health and disease. *Nature Immunology*. 2015;16(5):448-57.
29. Zhang X. Wu K. Wang D. Yue X. Song D. Zhu Y. et al. Nucleocapsid protein of SARS-CoV activates interleukin-6 expression through cellular transcription factor NF-kappaB. *Virology*. 2007;365(2):324-35.
30. Chen X. Zhao B. Qu Y. Chen Y. Xiong J. Feng Y. et al. Detectable serum SARS-CoV-2 viral load (RNAemia) is closely associated with drastically elevated interleukin 6 (IL-6) level in critically ill COVID-19 patients. *medRxiv*. 2020:2020.02.29.20029520.

31. Min C-K. Cheon S. Ha N-Y. Sohn KM. Kim Y. Aigerim A. et al. Comparative and kinetic analysis of viral shedding and immunological responses in MERS patients representing a broad spectrum of disease severity. *Scientific Reports*. 2016;6(1):25359.
32. Chien JY. Hsueh PR. Cheng WC. Yu CJ. Yang PC. Temporal changes in cytokine/chemokine profiles and pulmonary involvement in severe acute respiratory syndrome. *Respirology*. 2006;11(6):715-22.
33. Wang G. Wu C. Zhang Q. Wu F. Yu B. Lv J. et al. C-Reactive Protein Level May Predict the Risk of COVID-19 Aggravation. *Open Forum Infect Dis*. 2020;7(5):ofaa153.
34. Zeng F. Huang Y. Guo Y. Yin M. Chen X. Xiao L. et al. Association of inflammatory markers with the severity of COVID-19: A meta-analysis. *International Journal of Infectious Diseases*. 2020;96:467-74.
35. Hussman JP. Cellular and Molecular Pathways of COVID-19 and Potential Points of Therapeutic Intervention. *Front Pharmacol*. 2020;11:1169.
36. Bertolini A. van de Peppel IP. Bodewes F. Moshage H. Fantin A. Farinati F. et al. Abnormal liver function tests in COVID-19 patients: relevance and potential pathogenesis. *Hepatology*. 2020.
37. Hundt MA. Deng Y. Ciarleglio MM. Nathanson MH. Lim JK. Abnormal Liver Tests in COVID-19: A Retrospective Observational Cohort Study of 1827 Patients in a Major U.S. Hospital Network. *Hepatology*. 2020.
38. Batteux B. Bodeau S. Gras-Champel V. Liabeuf S. Lanoix JP. Schmit JL. et al. Abnormal laboratory findings and plasma concentration monitoring of lopinavir and ritonavir in COVID-19. *Br J Clin Pharmacol*. 2020.